KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Gains from Investment Securities (2019 - 2024)

Historic Gains from Investment Securities for GoodRx Holdings (GDRX) over the last 6 years, with Q4 2024 value amounting to $21.7 million.

  • GoodRx Holdings' Gains from Investment Securities rose 2601.64% to $21.7 million in Q4 2024 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 7035.45%. This contributed to the annual value of $23.6 million for FY2024, which is 3700.05% up from last year.
  • Per GoodRx Holdings' latest filing, its Gains from Investment Securities stood at $21.7 million for Q4 2024, which was up 2601.64% from $17.2 million recorded in Q4 2023.
  • GoodRx Holdings' 5-year Gains from Investment Securities high stood at $97.1 million for Q3 2021, and its period low was -$18.6 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $20.9 million, with a median of $16.6 million in 2022.
  • The largest annual percentage gain for GoodRx Holdings' Gains from Investment Securities in the last 5 years was 123571.43% (2021), contrasted with its biggest fall of 12133.79% (2021).
  • Over the past 5 years, GoodRx Holdings' Gains from Investment Securities (Quarter) stood at $87.3 million in 2020, then tumbled by 121.34% to -$18.6 million in 2021, then soared by 130.24% to $5.6 million in 2022, then surged by 206.05% to $17.2 million in 2023, then rose by 26.02% to $21.7 million in 2024.
  • Its last three reported values are $21.7 million in Q4 2024, $17.2 million for Q4 2023, and $666000.0 during Q1 2023.